Over the past five years, ICON has participated in 792 oncology and haematologic malignancy, and 73 non-malignant haematology, clinical studies globally. Meet ICON experts at #ASH24, booth #2101 to learn how our flexible and fully customisable solutions support all elements of drug development from candidate selection through to market authorisation and patient access https://ow.ly/NWEp50U7Tw4
Over ons
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
Externe link voor ICON plc
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- Meer dan 10.000 werknemers
- Hoofdkantoor
- Dublin
- Type
- Naamloze vennootschap
- Specialismen
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs en Global Patient Insights & Engagement
Locaties
Medewerkers van ICON plc
Updates
-
Excited to kick off #ISPOREurope with 19 poster presentations covering #vaccines, #oncology, #rarediseases, #infectiousideases, #diabetes and #cardiovascular. View all of the posters from the ICON team using the conference app! https://lnkd.in/ejHyHMbN
-
Small and emerging biotech have unique needs that a large CRO may be uniquely positioned to fill. Beyond clinical execution, the right partner can assistance with fundraising, strategic planning and go-to-market strategies, or bolstering executive capabilities to help position your company for long-term success. Learn more: https://ow.ly/7F9e50TQBLm #ICONbiotech #biotech #CRO #clinicalresearch #drugdevelopment
-
-
We are proud to share that for the fourth consecutive year, ICON participated in Run in the Dark, and 2024 turned out to be our best year yet! This year ICON employees are supporting Collaborative Cures and their inspiring mission to cure paralysis in our lifetime. Run in the Dark provides the opportunity for colleagues to come together for a powerful cause whilst simultaneously showing the positive impact movement can have for mental and physical wellbeing. This year, we had an incredible turnout, with participants joining Flagship Events, Pop-Up Events, and virtual runs in many of our operating countries. A huge thank you to everyone who connected with colleagues, laced up their running shoes, and made a real difference for Collaborative Cures. Those of you who still have your Run in the Dark planned Good Luck and we look forward to seeing more photo's! Read more about Collaborative Cures here: https://ow.ly/m2zo50U6Ynp
-
-
-
-
-
+1
-
-
Join us for an overview of systematic literature reviews, detailing their purpose, execution, decision-making criteria, and suitability for addressing key questions in the pharmaceutical industry. Register today for the webinar https://ow.ly/waK750TZ8zj
-
-
“I know first-hand how rewarding a career in life sciences can be, and the opportunities that exist.” In this interview, Rose Kidd, President, Operations Delivery at ICON and winner of the WMB Businesswoman Award for 2024 talks challenges and opportunities in the life sciences sector, the importance of a resilience mindset, and how we can support the progression of female leaders. Read more: https://ow.ly/zJPn50U6Men
-
-
N-of-1 trials have innovative utility for Rare Disease clinical research, though they are currently underutilised. Watch our panel discussion on the importance of N-of-1 trials in Rare Disease and personalised medicine https://ow.ly/9tMH50U26Il
-
-
ICON has a range of central laboratory solutions to support the specific needs of biotech companies operating in complex and rapidly evolving drug development environments. Find out more: https://ow.ly/iWiY50TJuX5
-
-
Interested in #vaccines, #oncology, #rarediseases, #infectiousideases, #diabetes and #cardiovascular? ICON has 19 posters covering those topics and more at #ISPOREurope. Don't miss this opportunity to learn and engage https://lnkd.in/ejHyHMbN
-
Research shows that 1 in 10 adults have diabetes, but nearly half of all diabetes cases are undiagnosed. FIRECREST is happy to support #WorldDiabetesDay to encourage diabetes awareness and education https://ow.ly/UpyA50U6ISW #WDD2024 https://ow.ly/iAlz50U6ISY
-
Gerelateerde pagina’s
Vergelijkbare pagina’s
Door vacatures bladeren
Financiering
ICON plc
1 ronde in totaal
Bekijk meer informatie over Crunchbase
Laatste ronde
Schuld na beursgang
Externe Crunchbase-link voor laatste financieringsronde
US$ 2.000.000.000,00